Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.40 |
| ▸ | METAP2 | P50579 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7624006 | 1.00 | KDM4E (0.46) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL3658524 | 0.83 | KDM4E (0.46) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL2762810 | 0.83 | KDM4E (0.46) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL4553803 | 0.79 | KDM4E (0.44) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL3831520 | 0.73 | BCAT2 (0.46) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL731619 | 0.72 | IRAK4 (0.52) | KDM4EALDH1A1HPGDMAPTBCAT2 | |
| SCHEMBL105262 | 0.71 | IRAK4 (0.55) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL31632660 | 0.71 | IRAK4 (0.55) | KDM4EALDH1A1HPGDMAPTLMNA | |
| SCHEMBL4431290 | 0.71 | KDM4E (0.47) | KDM4EALDH1A1HPGDMAPTBCAT2 | |
| Hydrochloric Acid SCHEMBL3683840 | 0.71 | IRAK4 (0.50) | KDM4EALDH1A1HPGDMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120746-A1 | USE OF R-10-HYDROXY-10,11-DIHYDRO-CARBAMAZEPINE IN NEUROPATHIC PAIN | FOX ALYSON | 2010-05-13 | — | — | US | disclosed |
| US-20100063029-A1 | USE OF S-10-HYDROXY-10,11-DIHYDRO-CARBAMAZEPINE FOR THE TREATMENT OF ANXIETY AND BIPOLAR DISORDERS | BILBE GRAEME | 2010-03-11 | — | — | US | disclosed |
| US-7638510-B2 | Use of s-10-hydroxy-10,11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders | NOVARTIS AG (CH) | 2009-12-29 | — | — | US | disclosed |
| US-20090054404-A1 | USE OF R-10-HYDROXY-10,11-DIHYDRO-CARBAMAZEPINE IN NEUROPATHIC PAIN | FOX ALYSON | 2009-02-26 | — | — | US | disclosed |
| US-7465723-B2 | Use of carboxamides for the treatment of tinnitus | NOVARTIS (US) | 2008-12-16 | — | — | US | disclosed |
| CN-100356923-C | Use of s-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders | NOVARTIS AG (CH) | 2007-12-26 | — | — | CN | disclosed |
| US-20070196488-A1 | Oral matrix formulations comprising licarbazepine | NOVARTIS AG (CH) | 2007-08-23 | — | — | US | disclosed |
| US-20070190143-A1 | Disintegrating tablets comprising licarb azepine | NOVARTIS AG (CH) | 2007-08-16 | — | — | US | disclosed |
| CN-1933817-A | Disintegrating tablets comprising licarbazepine | NOVARTIS AG (CH) | 2007-03-21 | — | — | CN | disclosed |
| CN-1933819-A | Oral matrix formulations comprising licarbazepine | NOVARTIS AG (CH) | 2007-03-21 | — | — | CN | disclosed |
| EP-1551808-A1 | ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ b,f AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF | Novartis AG (CH) | 2005-07-13 | — | — | EP | disclosed |
| EP-1528927-A1 | USE OF CARBOXAMIDES FOR THE TREATMENT OF TINNITUS | Novartis AG (CH) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004087168-A1 | USE OF 10-HYDROXY-10,11-DIHYDROCARBAMAZEPINE DERIVATIVES FOR THE TREATMENT OF AFFECTIVE DISORDERS | NOVARTIS AG (CH) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004071152-A2 | USE OF S-10 HYDROXY-10, 11-DIHYDRO-CARBAMAZEPINE FOR THE TREATMENT OF ANXIETY AND BIPOLAR DISORDERS | NOVARTIS AG (CH) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004071513-A1 | USE OF R-10-HYDROXY-10, 11-DIHYDRO-CARBAMAZEPINE IN NEUROPATHIC PAIN | NOVARTIS AG (CH) | 2004-08-26 | — | — | WO | disclosed |
| WO-2004031155-A1 | ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF | NOVARTIS AG (CH) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004014391-A1 | USE OF CARBOXAMIDES FOR THE TREATMENT OF TINNITUS | NOVARTIS AG (CH) | 2004-02-19 | — | — | WO | disclosed |
| EP-0915076-B1 | Process for the preparation of trans-(R,R)-actinol | HOFFMANN LA ROCHE (CH) | 2002-01-16 | — | — | EP | disclosed |
| US-6187961-B1 | HYDROGENATING (R)-LEVODIONE IN PRESENCE OF HYDROGEN DONAR AND A SOLVENT OR IN PRESENCE OF HYDROGEN DONOR WHICH SIMULTANEOUSLY USED AS THE SOLVENT, AND AN AMINO-AMIDE-RUTHENIUM COMPLEX | ROCHE VITAMINS INC. | 2001-02-13 | — | — | US | disclosed |
| EP-0915076-A1 | Process for the preparation of trans-(R,R)-actinol | F. HOFFMANN-LA ROCHE AG (CH) | 1999-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120746-A1 | USE OF R-10-HYDROXY-10,11-DIHYDRO-CARBAMAZEPINE IN NEUROPATHIC PAIN | SCN10A, SCN11A, SCN5A | KDM4E 1928/4885ALDH1A1 1169/4885HPGD 153/4885 |
| US-20100063029-A1 | USE OF S-10-HYDROXY-10,11-DIHYDRO-CARBAMAZEPINE FOR THE TREATMENT OF ANXIETY AND BIPOLAR DISORDERS | ACAD11, SCN11A, CHRNA10 | KDM4E 3012/4885ALDH1A1 109/4885HPGD 315/4885 |
| US-20090054404-A1 | USE OF R-10-HYDROXY-10,11-DIHYDRO-CARBAMAZEPINE IN NEUROPATHIC PAIN | SCN10A, SCN11A, SCN5A | KDM4E 2132/4885ALDH1A1 1223/4885HPGD 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.